SG10201810888XA - Compositions and methods comprising bupropion or related compounds and dextromethorphan - Google Patents
Compositions and methods comprising bupropion or related compounds and dextromethorphanInfo
- Publication number
- SG10201810888XA SG10201810888XA SG10201810888XA SG10201810888XA SG10201810888XA SG 10201810888X A SG10201810888X A SG 10201810888XA SG 10201810888X A SG10201810888X A SG 10201810888XA SG 10201810888X A SG10201810888X A SG 10201810888XA SG 10201810888X A SG10201810888X A SG 10201810888XA
- Authority
- SG
- Singapore
- Prior art keywords
- dextromethorphan
- bupropion
- compositions
- methods
- related compounds
- Prior art date
Links
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 title abstract 4
- 229960001985 dextromethorphan Drugs 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229960001058 bupropion Drugs 0.000 title abstract 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001430 anti-depressive effect Effects 0.000 abstract 2
- 239000000935 antidepressant agent Substances 0.000 abstract 2
- 229940005513 antidepressants Drugs 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
COMPOSITIONS AND METHODS COMPRISING BUPROPION OR RELATED COMPOUNDS AND DEXTROMETHORPHAN This disclosure relates to a method of treating a neurological disorder by administering an antidepressant compound and dextromethorphan to a human being in need thereof. This may useful human that extensive etabolizers dextromethorphan. medicaments, dosage comprising antidepressant and omethorphan also d. Figure 7
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900354P | 2013-11-05 | 2013-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201810888XA true SG10201810888XA (en) | 2019-01-30 |
Family
ID=53042051
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201603391XA SG11201603391XA (en) | 2013-11-05 | 2014-11-05 | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
| SG10201810888XA SG10201810888XA (en) | 2013-11-05 | 2014-11-05 | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
| SG10201911808QA SG10201911808QA (en) | 2013-11-05 | 2014-11-05 | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
| SG10201911816XA SG10201911816XA (en) | 2013-11-05 | 2014-11-05 | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201603391XA SG11201603391XA (en) | 2013-11-05 | 2014-11-05 | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201911808QA SG10201911808QA (en) | 2013-11-05 | 2014-11-05 | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
| SG10201911816XA SG10201911816XA (en) | 2013-11-05 | 2014-11-05 | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
Country Status (12)
| Country | Link |
|---|---|
| EP (3) | EP3981404A1 (en) |
| JP (4) | JP6605485B2 (en) |
| KR (4) | KR20230148385A (en) |
| CN (7) | CN110279682A (en) |
| AU (6) | AU2014346807B2 (en) |
| CA (3) | CA3154845C (en) |
| IL (3) | IL298972A (en) |
| MX (3) | MX2016005867A (en) |
| MY (1) | MY179696A (en) |
| NZ (5) | NZ758431A (en) |
| SG (4) | SG11201603391XA (en) |
| WO (1) | WO2015069809A1 (en) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11253491B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11517543B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11524007B2 (en) | 2013-11-05 | 2022-12-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| CA3154845C (en) * | 2013-11-05 | 2023-02-28 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
| US11497721B2 (en) | 2013-11-05 | 2022-11-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11298352B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11197839B2 (en) | 2013-11-05 | 2021-12-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20200338022A1 (en) | 2019-01-07 | 2020-10-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11253492B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11291665B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11191739B2 (en) | 2013-11-05 | 2021-12-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11439636B1 (en) | 2013-11-05 | 2022-09-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11617747B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426370B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426401B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11382874B2 (en) | 2013-11-05 | 2022-07-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11357744B2 (en) | 2013-11-05 | 2022-06-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11207281B2 (en) | 2013-11-05 | 2021-12-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11478468B2 (en) | 2013-11-05 | 2022-10-25 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11147808B2 (en) | 2013-11-05 | 2021-10-19 | Antecip Bioventures Ii Llc | Method of decreasing the fluctuation index of dextromethorphan |
| US11590124B2 (en) | 2013-11-05 | 2023-02-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11285118B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11510918B2 (en) | 2013-11-05 | 2022-11-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11571417B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11419867B2 (en) | 2013-11-05 | 2022-08-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11344544B2 (en) | 2013-11-05 | 2022-05-31 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11364233B2 (en) | 2013-11-05 | 2022-06-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20220233470A1 (en) | 2013-11-05 | 2022-07-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11576909B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11571399B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11617728B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11596627B2 (en) | 2013-11-05 | 2023-03-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11273133B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11541048B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11311534B2 (en) | 2013-11-05 | 2022-04-26 | Antecip Bio Ventures Ii Llc | Bupropion as a modulator of drug activity |
| US11229640B2 (en) | 2013-11-05 | 2022-01-25 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11123344B2 (en) | 2013-11-05 | 2021-09-21 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
| US11129826B2 (en) | 2013-11-05 | 2021-09-28 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
| US11576877B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as modulator of drug activity |
| US11234946B2 (en) | 2013-11-05 | 2022-02-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11541021B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11298351B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| TW202231278A (en) * | 2014-09-14 | 2022-08-16 | 美商阿瓦尼爾製藥股份有限公司 | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia |
| AU2015350559C1 (en) * | 2014-11-21 | 2019-07-11 | Antecip Bioventures Ii Llc | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| EP3432885A4 (en) * | 2016-03-24 | 2019-11-20 | Antecip Bioventures II LLC | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| TWI795446B (en) * | 2017-10-04 | 2023-03-11 | 美商神經治療股份有限公司 | Dextromethorphan transdermal delivery device |
| KR20210110654A (en) * | 2019-01-07 | 2021-09-08 | 안테씨프 바이오벤쳐스 투 엘엘씨 | Combination of dextromethorphan and bupropion for the treatment of depression |
| EP4125837A4 (en) * | 2020-03-30 | 2024-03-20 | Antecip Bioventures Ii Llc | Use of bupropion and dextromethorphan combinations for treating neurological disorders |
| CN114340608B (en) * | 2020-07-20 | 2023-10-31 | 深圳信立泰药业股份有限公司 | Pharmaceutical composition and application thereof |
| KR20230113787A (en) | 2020-12-01 | 2023-08-01 | 안테씨프 바이오벤쳐스 투 엘엘씨 | Bupropion and dextromethorphan for reducing the risk of suicide in depressed patients |
| CN116981450A (en) * | 2021-01-18 | 2023-10-31 | 安泰赛普生物风投二代有限责任公司 | Combination of antidepressants and dextromethorphan for the treatment of neuropsychiatric disorders |
| CN112999350A (en) * | 2021-02-23 | 2021-06-22 | 北京斯利安药业有限公司 | Pharmaceutical composition, compound preparation, and preparation method and application thereof |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US11844797B1 (en) | 2023-04-20 | 2023-12-19 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350756A (en) * | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| EP0980247A1 (en) * | 1997-05-07 | 2000-02-23 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
| TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| WO2007092329A2 (en) * | 2006-02-03 | 2007-08-16 | Avanir Pharmaceuticals | Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders |
| WO2009006194A1 (en) | 2007-06-28 | 2009-01-08 | Avanir Pharmaceuticals | Pharmaceutical compositions for the treatment of involuntary emotional expression disorder |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US20130274282A1 (en) | 2012-04-16 | 2013-10-17 | Herriot Tabuteau | Compositions and methods comprising celecoxib or related compounds and dextromethorphan |
| CA3154845C (en) * | 2013-11-05 | 2023-02-28 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
-
2014
- 2014-11-05 CA CA3154845A patent/CA3154845C/en active Active
- 2014-11-05 CA CA2929415A patent/CA2929415C/en active Active
- 2014-11-05 KR KR1020237034772A patent/KR20230148385A/en active Application Filing
- 2014-11-05 MX MX2016005867A patent/MX2016005867A/en active IP Right Grant
- 2014-11-05 IL IL298972A patent/IL298972A/en unknown
- 2014-11-05 SG SG11201603391XA patent/SG11201603391XA/en unknown
- 2014-11-05 MX MX2020004075A patent/MX2020004075A/en unknown
- 2014-11-05 MY MYPI2016701609A patent/MY179696A/en unknown
- 2014-11-05 NZ NZ758431A patent/NZ758431A/en unknown
- 2014-11-05 CN CN201910649207.4A patent/CN110279682A/en active Pending
- 2014-11-05 SG SG10201810888XA patent/SG10201810888XA/en unknown
- 2014-11-05 NZ NZ758432A patent/NZ758432A/en unknown
- 2014-11-05 NZ NZ719892A patent/NZ719892A/en unknown
- 2014-11-05 SG SG10201911808QA patent/SG10201911808QA/en unknown
- 2014-11-05 KR KR1020227013910A patent/KR102603013B1/en active IP Right Grant
- 2014-11-05 JP JP2016552474A patent/JP6605485B2/en active Active
- 2014-11-05 CN CN202111061009.XA patent/CN113750098A/en active Pending
- 2014-11-05 EP EP21191393.4A patent/EP3981404A1/en active Pending
- 2014-11-05 CN CN202111061803.4A patent/CN113797205A/en active Pending
- 2014-11-05 EP EP21191390.0A patent/EP3981403A1/en active Pending
- 2014-11-05 KR KR1020167013970A patent/KR102264179B1/en active IP Right Grant
- 2014-11-05 NZ NZ758428A patent/NZ758428A/en unknown
- 2014-11-05 EP EP14859589.5A patent/EP3065742A4/en active Pending
- 2014-11-05 AU AU2014346807A patent/AU2014346807B2/en active Active
- 2014-11-05 KR KR1020217016618A patent/KR20210068157A/en active Application Filing
- 2014-11-05 CN CN201910649198.9A patent/CN110327338A/en active Pending
- 2014-11-05 CN CN201480072191.0A patent/CN106163522A/en active Pending
- 2014-11-05 SG SG10201911816XA patent/SG10201911816XA/en unknown
- 2014-11-05 CN CN201910649199.3A patent/CN110251517A/en active Pending
- 2014-11-05 CA CA3175703A patent/CA3175703A1/en active Pending
- 2014-11-05 NZ NZ758425A patent/NZ758425A/en unknown
- 2014-11-05 CN CN202111061795.3A patent/CN113750099A/en active Pending
- 2014-11-05 WO PCT/US2014/064184 patent/WO2015069809A1/en active Application Filing
-
2016
- 2016-05-04 MX MX2021015234A patent/MX2021015234A/en unknown
- 2016-05-05 IL IL245504A patent/IL245504B/en active IP Right Grant
-
2018
- 2018-05-23 AU AU2018203638A patent/AU2018203638C1/en active Active
-
2019
- 2019-09-23 AU AU2019236614A patent/AU2019236614C1/en active Active
- 2019-10-16 JP JP2019189318A patent/JP6927601B2/en active Active
- 2019-12-04 AU AU2019275593A patent/AU2019275593B2/en active Active
-
2021
- 2021-04-23 AU AU2021202497A patent/AU2021202497B2/en active Active
- 2021-06-07 IL IL283760A patent/IL283760B2/en unknown
- 2021-07-29 JP JP2021124094A patent/JP2021169527A/en active Pending
-
2023
- 2023-06-01 AU AU2023203438A patent/AU2023203438A1/en active Pending
- 2023-07-27 JP JP2023122146A patent/JP2023129646A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201810888XA (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
| BR112014028017A2 (en) | compound, pharmaceutical composition, method for treating a disorder, method for reducing the amount of il-17 in an individual, and method for inhibiting ror activity | |
| IN2015DN03219A (en) | ||
| MX2018003893A (en) | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough. | |
| NZ630367A (en) | Methods of treatment of pediatric solid tumor | |
| MX2016004741A (en) | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent. | |
| MX2015004362A (en) | Ketamine derivatives. | |
| UA113962C2 (en) | PHARMACEUTICAL COMPOSITION CONTAINING APOMORPHINE AS AN ACTIVE INGREDIENT | |
| MD20160007A2 (en) | Heterobicycloaryl RORC2 inhibitors and methods of use thereof | |
| EA201691918A1 (en) | PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | |
| WO2015058664A8 (en) | Use of icaritin in preparing medicament for preventing or treating hematocytopenia | |
| MY192813A (en) | Aqueous formulation comprising paracetamol and ibuprofen | |
| SG10201907291QA (en) | Monomethylfumarate prodrug compositions | |
| EA201591507A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS BY LACHINIMODOM | |
| MX2018014129A (en) | Pharmaceutical composition comprising eteplirsen. | |
| MX2020001428A (en) | Compositions of grapiprant and methods for using the same. | |
| MX2015012455A (en) | Method for the treatment of fatty liver disease. | |
| MX366309B (en) | Pharmaceutical composition for treating inflammation and pain. | |
| SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
| WO2015027121A3 (en) | Cancer treatment | |
| MX368640B (en) | PHARMACEUTICAL COMPOSITION FOR TREATING INFLAMMATION and PAIN. | |
| MX365021B (en) | Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient. |